1-2 of 2
Maria Balasis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

Free
Warren Fiskus, Michael Pranpat, Maria Balasis, Purva Bali, Veronica Estrella, Sandhya Kumaraswamy, Rekha Rao, Kathy Rocha, Bryan Herger, Francis Lee, Victoria Richon, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5869–5878.
https://doi.org/10.1158/1078-0432.CCR-06-0980
Published: 04 October 2006
View articletitled, Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells
Open the PDF for Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells in another window
Journal Articles

Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

Free
Purva Bali, Michael Pranpat, Ramona Swaby, Warren Fiskus, Hirohito Yamaguchi, Maria Balasis, Kathy Rocha, Hong-Gang Wang, Victoria Richon, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6382–6389.
https://doi.org/10.1158/1078-0432.CCR-05-0344
Published: 06 September 2005
View articletitled, Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Open the PDF for Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 in another window